Zomato founder Deepinder Goyal's personal health-tech startup, Temple, has unveiled the research team behind its BrainFlow wearable. The device, which tracks brain blood volume, is expected to open for pre-orders within a week. This project is an independent venture separate from Zomato.
Zomato founder Deepinder Goyal has provided a status update on his independent health-tech venture, Temple. The startup is developing a wearable device called BrainFlow, which is designed to track cerebral blood flow continuously. The company, which operates separately from Zomato, has announced that pre-orders for the device are expected to open within the next seven days.
The core technology behind the product involves continuous monitoring of brain blood volume, a task that has historically been difficult for wearable hardware. To achieve this, the company has assembled a research team featuring experts from the Indian Institute of Science (IISc), the Indian Institute of Technology (IIT) Bombay, and international academic institutions.
Solving the Measurement Challenge
A key hurdle in brain monitoring hardware is scalp interference, where readings are blurred by blood flow in the skin rather than the brain. To address this, Temple conducted a study involving 60 participants who were subjected to various physical stressors, such as posture changes and head-down tilts. The study, supervised by Prof. David Boas from Boston University, utilized time-domain near-infrared spectroscopy to filter out signals from the scalp.
The company claims that these results prove the device can accurately isolate brain blood volume data. While the study findings are currently undergoing peer review, the startup has chosen to adopt an open-science model. Goyal has stated that the technology and metrics will be accessible to qualified researchers who wish to perform independent testing.
Context for Investors
For market participants, it is important to distinguish between this initiative and Zomato. Temple is a personal venture of the founder and does not represent a business segment or subsidiary of the listed entity, Zomato.
As an early-stage hardware project, the venture faces typical risks associated with bringing new medical-grade technology to market, including manufacturing scalability, potential regulatory compliance, and consumer adoption. The upcoming pre-order window will be the first major commercial test for the project, allowing the company to gauge demand and refine its operational roadmap. Investors may track the actual product delivery timeline and the reception of the device by the medical and fitness research community as the next steps in the startup's development.